Regulus Therapeutics (NASDAQ:RGLS) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) to a sell rating in a research report released on Friday morning.

RGLS has been the topic of a number of other research reports. HC Wainwright restated a buy rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research report on Friday, August 9th. Oppenheimer reissued an outperform rating and set a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, August 14th. Finally, Canaccord Genuity Group upped their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a buy rating in a report on Tuesday, June 25th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics currently has a consensus rating of Moderate Buy and an average price target of $10.80.

Regulus Therapeutics Stock Performance

Shares of RGLS opened at $1.51 on Friday. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79. The firm has a market cap of $98.86 million, a price-to-earnings ratio of -1.02 and a beta of 1.63. The business’s fifty day moving average is $1.67 and its 200-day moving average is $2.04.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). As a group, research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new stake in shares of Regulus Therapeutics during the second quarter worth $136,000. Renaissance Technologies LLC grew its holdings in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 42,600 shares during the period. Victory Capital Management Inc. raised its position in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth about $352,000. Finally, Opaleye Management Inc. acquired a new position in shares of Regulus Therapeutics in the 1st quarter valued at about $490,000. Institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.